Erasca announces issuance of U.S. patent covering ERAS-0015

Erasca (ERAS) announced that the U.S. Patent and Trademark Office has issued Patent No. 12,458,647, titled “Macrocyclic Derivative And Use Thereof.” The patent claims protect the composition of matter for Erasca’s potentially best-in-class pan-RAS molecular glue ERAS-0015 and related compositions until September 2043, which may be subject to patent term adjustments or extensions affording even later protection. “This U.S. patent is a foundational milestone for our ERAS-0015 program, further highlighting our efficient execution across this program since its in-licensing in May 2024,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “Covering ERAS-0015 until at least 2043, this patent is among a series of patent filings designed to form a strong and durable intellectual property portfolio for our RAS-targeting franchise. We look forward to initial Phase 1 monotherapy data for ERAS-0015 and pan-KRAS inhibitor ERAS-4001, both of which are expected in 2026.”